Eyenovia, Inc.

EYEN

US30234E1047

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6282 ^USD	-11.68%		+10.09%	-69.80%

Apr. 25	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	CI
Apr. 08	Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	MT

Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000E Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about Eyenovia, Inc.

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	Apr. 25	CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	Apr. 08	MT
Eyenovia Explores Wide Range of Strategic Alternatives	Apr. 08	CI
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024	Mar. 18
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	Mar. 13	CI
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	Mar. 05	MT
US FDA approves Eyenovia's eye drug, Formosa Pharma says	Mar. 04	RE
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	Feb. 13	CI
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Eyenovia, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board	Nov. 09	CI
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production	Nov. 02	CI
William Blair Initiates Eyenovia at Outperform Rating	Nov. 01	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	23-08-25	MT
Eyenovia Prices $12 Million Registered Direct Offering	23-08-25	MT
Insider Buy: Eyenovia	23-08-17	MT
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa	23-08-16	MT
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	23-08-16	CI
Transcript : Eyenovia, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi	23-08-03	CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000 Index	23-06-23	CI
Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000E Growth Index	23-06-23	CI

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Association for Research in Vision and Ophthalmology Meeting - Presentation Number: 3991 - B0035

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Eyenovia, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6282 USD

Average target price

9.333 USD

Spread / Average Target

+1,385.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EYENOVIA, INC.	-69.80%	32.01M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Eyenovia, Inc.

Equities

EYEN

US30234E1047

Pharmaceuticals

Eyenovia, Inc.(NasdaqCM:EYEN) added to Russell 3000E Growth Index

Latest news about Eyenovia, Inc.

Chart Eyenovia, Inc.

Company Profile

Income Statement Evolution

Ratings for Eyenovia, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals